普托馬尼

普托馬尼
臨床資料
商品名（英语：Drug nomenclature）	Dovprela
其他名稱	PA-824
AHFS/Drugs.com	Monograph
MedlinePlus	a619056
核准狀況	美 DailyMed: Pretomanid;
给药途径	口服给药
ATC碼	J04AK08 (WHO) ;
法律規範狀態
法律規範	歐：Rx-only; 美：处方药（℞-only）;
识别信息
	IUPAC命名法 (6S)-2-Nitro-6[4-(trifluoromethoxy)benzyl]oxy6,7-dihydro-5H-imidazo[2,1-b] [1,3]oxazine; ;
CAS号	187235-37-6
PubChem CID	456199;
DrugBank	DB05154;
ChemSpider	401693 ;
UNII	2XOI31YC4N;
KEGG	D10722 ;
ChEMBL	ChEMBL227875 ;
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID8041163 ;
化学信息
化学式	C14H12F3N3O5
摩尔质量	359.26 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES C1[C@@H](COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F;
	InChI InChI=1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1 ; Key:ZLHZLMOSPGACSZ-NSHDSACASA-N ;

普托馬尼（Pretomanid）用于治疗影响肺部的多重抗藥性結核病（英语：Multidrug-resistant tuberculosis）^[4]。是一種口服给药的抗生素^[5]。常与貝達喹啉和利奈唑胺合併使用^[5]。

常见副作用包括周邊神經病變、痤疮、呕吐、头痛、低血糖、腹泻和肝炎^[4]。其他副作用包括可能骨髓抑制、視神經炎（英语：Optic neuropathy）和QT間期延長（英语：Drug-induced QT prolongation）^[6]。娠期的安全性仍不清楚^[7]。此药属于5-硝基咪唑类药物^[8]。

普托馬尼分別于2019年及2020年在美国及歐洲取得医疗使用許可^[4] ^[5]。名列世界卫生组织基本药物标准清单^[9]。此藥是由結核病聯盟（英语：TB Alliance）研发^[8] ^[4]。

参考文獻

^ Pretomanid tablet. DailyMed. 15 September 2019 [25 September 2020].
^ Dovprela (previously Pretomanid FGK) EPAR. European Medicines Agency (EMA). 24 March 2020 [25 September 2020]. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ Dovprela Product information. Union Register of medicinal products. [3 March 2023].
^ ^4.0 ^4.1 ^4.2 ^4.3 FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs. U.S. Food and Drug Administration (FDA) (新闻稿). 14 August 2019 [28 August 2019]. （原始内容存档于19 August 2019）. 本文含有此來源中屬於公有领域的内容。
^ ^5.0 ^5.1 ^5.2 Pretomanid FGK EPAR. European Medicines Agency (EMA). 24 March 2020 [25 September 2020]. （原始内容存档于20 October 2020）. 互联网档案馆的存檔，存档日期20 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ Pretomanid Monograph for Professionals. Drugs.com. [29 October 2021] （英语）.
^ Pretomanid Use During Pregnancy. Drugs.com. [29 October 2021] （英语）.
^ ^8.0 ^8.1 Our Pipeline. TB Alliance. [18 April 2019]. （原始内容存档于7 April 2019）. 互联网档案馆的存檔，存档日期7 April 2019.
^ World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. WHO/MHP/HPS/EML/2023.02.

[Pretomanid_FDA_label-1] Pretomanid tablet. DailyMed. 15 September 2019 [25 September 2020].

[Dovprela_EPAR-2] Dovprela (previously Pretomanid FGK) EPAR. European Medicines Agency (EMA). 24 March 2020 [25 September 2020]. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[3] Dovprela Product information. Union Register of medicinal products. [3 March 2023].

[FDA2019-4] 4.0 ^4.1 ^4.2 ^4.3 FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs. U.S. Food and Drug Administration (FDA) (新闻稿). 14 August 2019 [28 August 2019]. （原始内容存档于19 August 2019）. 本文含有此來源中屬於公有领域的内容。

[EPAR2021-5] 5.0 ^5.1 ^5.2 Pretomanid FGK EPAR. European Medicines Agency (EMA). 24 March 2020 [25 September 2020]. （原始内容存档于20 October 2020）. 互联网档案馆的存檔，存档日期20 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[AHFS2021-6] Pretomanid Monograph for Professionals. Drugs.com. [29 October 2021] （英语）.

[7] Pretomanid Use During Pregnancy. Drugs.com. [29 October 2021] （英语）.

[Tb2021-8] 8.0 ^8.1 Our Pipeline. TB Alliance. [18 April 2019]. （原始内容存档于7 April 2019）. 互联网档案馆的存檔，存档日期7 April 2019.

[WHO23rd-9] World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. WHO/MHP/HPS/EML/2023.02.

[2]

[3]

[1]

[4]

[5]

[6]

[7]

[8]

[9]